

Conference Abstract ● Free

Skeletal muscle dysfunction among COPD patients in Eastern Europe

Vitalii Poberezhets | Szymon Skoczylski | Anna Demchuk | Aleksandra Oraczewska | Ewelina Tobiczuk | Yuriy Mostovoy | Adam Barczyk [See Less ▾](#)European Respiratory Journal 2020 56(suppl 64): 2476; DOI: <https://doi.org/10.1183/13993003.congress-2020.2476>[Permissions](#) [Add to Favourites](#) [Labels](#) [Cite](#) [Share](#) [Alerts](#)This article appears in:
European Respiratory Journal
Vol 56 Issue suppl 64[Article](#) [Info & Metrics](#)[Focus](#) [Previous](#) [Next](#)

Abstract

Introduction: Skeletal muscle dysfunction (SMD) is characterized by loss of muscle cells and abnormal function of the remaining cells. Detecting patients with low muscle strength in the early stages could help to prevent complications.

Aims: Our study aimed to determine prevalence of low muscle strength and SMD among COPD patients and clinical features of these patients.

Methods: We examined 181 COPD patients (170 men) in Ukraine and Poland. Mean age 69.9±10.6 years, FEV1 46.1±14.4%, FEV1/FVC ratio 59.7±18.0%, Charlson Comorbidity Index 2.6±1.4. We evaluated muscle quantity using bioelectric impedance analysis, muscle strength – using hand-grip dynamometry, physical performance – using gait speed by 6-minute walk test, life quality – using St. George's respiratory questionnaire, symptoms – using CAT test.

Results: SMD was present in 93 patients (51.4%) (severe sarcopenia was present in 26 patients among them (14.4%)), low muscle strength – in 15 patients (8.3%). Persons with low muscle strength had significantly higher CAT score than ones without muscle damage (21.0±9.7/15.5±6.2 (p=0.02)). Comparing to patients without muscle damage, patients with SMD had significantly worse, life quality (60.6±16.4/52.6±15.0 (p=0.004)), CAT score (19.4±7.4/15.5±6.2 (p=0.002)), FEV1 (41.6±17.8/52.3±15.6% (p<0.001)), FEV1/FVC ratio (55.0±17.8/65.6±16.7% (p=0.006)) and had lower fat-mass index (5.7±4.5/9.7±7.3 kg/m² (p<0.001)).

Conclusions: Isolated low muscle strength was present in every twelfth COPD patient that had more severe symptoms. SMD affected half of the COPD patients had worse lung function, exercise capacity, symptoms, life quality and the lowest containing of body fat.

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 2476.

This abstract was presented at the 2020 ERS International Congress, in session "Respiratory viruses in the "pre COVID-19" era".

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

Related Articles

[Impact of comorbidities on the deterioration ...](#)[COPD patients with skeletal muscle dysfunction...](#)[Features of skeletal muscle dysfunction in CO...](#)[Show More ▾](#)

Related Books

[COPD and Comorbidity](#)[Controversies in COPD](#)[COPD in the 21st Century](#)

Related Book Chapters

[Managing skeletal muscle dysfunction in COPD](#)[Respiratory and skeletal muscles in chronic o...](#)[Malnutrition and obesity in COPD](#)